These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 31230551)

  • 1. Angs (Angiotensins) of the Alternative Renin-Angiotensin System Predict Outcome in Patients With Heart Failure and Preserved Ejection Fraction.
    Binder C; Poglitsch M; Agibetov A; Duca F; Zotter-Tufaro C; Nitsche C; Aschauer S; Kammerlander AA; Oeztuerk B; Hengstenberg C; Mascherbauer J; Bonderman D
    Hypertension; 2019 Aug; 74(2):285-294. PubMed ID: 31230551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of the renin-angiotensin system on cardiac energy metabolism in heart failure.
    Mori J; Zhang L; Oudit GY; Lopaschuk GD
    J Mol Cell Cardiol; 2013 Oct; 63():98-106. PubMed ID: 23886814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of left ventricular ejection fraction on the effect of renin-angiotensin system blockers after an episode of acute heart failure: From the KCHF Registry.
    Yoshikawa Y; Tamaki Y; Morimoto T; Yaku H; Yamamoto E; Inuzuka Y; Ozasa N; Kitai T; Nagao K; Sato Y; Kondo H; Tamura T; Nakagawa Y; Kuwahara K; Kato T; Kimura T
    PLoS One; 2020; 15(9):e0239100. PubMed ID: 32925953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of renin-angiotensin system inhibitors on mortality and heart failure hospitalization in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis.
    Shah RV; Desai AS; Givertz MM
    J Card Fail; 2010 Mar; 16(3):260-7. PubMed ID: 20206902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and Outcomes in Heart Failure: A Meta-Analysis.
    Khan MS; Fonarow GC; Ahmed A; Greene SJ; Vaduganathan M; Khan H; Marti C; Gheorghiade M; Butler J
    Circ Heart Fail; 2017 Aug; 10(8):. PubMed ID: 28790052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation pattern of ACE2/Ang-(1-7) and ACE/Ang II pathway in course of heart failure assessed by multiparametric MRI in vivo in Tgαq*44 mice.
    Tyrankiewicz U; Olkowicz M; Skórka T; Jablonska M; Orzylowska A; Bar A; Gonet M; Berkowicz P; Jasinski K; Zoladz JA; Smolenski RT; Chlopicki S
    J Appl Physiol (1985); 2018 Jan; 124(1):52-65. PubMed ID: 28970203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated Angiotensin 1-7/Angiotensin II Ratio Predicts Favorable Outcomes in Patients With Heart Failure.
    Wang K; Basu R; Poglitsch M; Bakal JA; Oudit GY
    Circ Heart Fail; 2020 Jul; 13(7):e006939. PubMed ID: 32580658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Optimal Plasma Volume Status in Heart Failure in Relation to Clinical Outcome.
    Martens P; Nijst P; Dupont M; Mullens W
    J Card Fail; 2019 Apr; 25(4):240-248. PubMed ID: 30528705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of angiotensin-converting-enzyme inhibitor therapy on the regulation of the plasma and cardiac tissue renin-angiotensin system in heart transplant patients.
    Kovarik JJ; Kopecky C; Antlanger M; Domenig O; Kaltenecker CC; Werzowa J; Hecking M; Mahr S; Grömmer M; Wallner C; Aumayr K; Kain R; Zuckermann A; Poglitsch M; Säemann MD
    J Heart Lung Transplant; 2017 Mar; 36(3):355-365. PubMed ID: 27773450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renin-Angiotensin System Inhibition, Worsening Renal Function, and Outcome in Heart Failure Patients With Reduced and Preserved Ejection Fraction: A Meta-Analysis of Published Study Data.
    Beldhuis IE; Streng KW; Ter Maaten JM; Voors AA; van der Meer P; Rossignol P; McMurray JJ; Damman K
    Circ Heart Fail; 2017 Feb; 10(2):. PubMed ID: 28209765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of renin-angiotensin system blockade on mortality and hospitalization in heart failure with preserved ejection fraction.
    Agarwal V; Briasoulis A; Messerli FH
    Heart Fail Rev; 2013 Jul; 18(4):429-37. PubMed ID: 22678768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of the ACE2/Angiotensin 1-7 Axis of the Renin-Angiotensin System in Heart Failure.
    Patel VB; Zhong JC; Grant MB; Oudit GY
    Circ Res; 2016 Apr; 118(8):1313-26. PubMed ID: 27081112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE).
    Komajda M; Carson PE; Hetzel S; McKelvie R; McMurray J; Ptaszynska A; Zile MR; Demets D; Massie BM
    Circ Heart Fail; 2011 Jan; 4(1):27-35. PubMed ID: 21068341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between use of renin-angiotensin system antagonists and mortality in patients with heart failure and preserved ejection fraction.
    Lund LH; Benson L; Dahlström U; Edner M
    JAMA; 2012 Nov; 308(20):2108-17. PubMed ID: 23188027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potassium and the use of renin-angiotensin-aldosterone system inhibitors in heart failure with reduced ejection fraction: data from BIOSTAT-CHF.
    Beusekamp JC; Tromp J; van der Wal HH; Anker SD; Cleland JG; Dickstein K; Filippatos G; van der Harst P; Hillege HL; Lang CC; Metra M; Ng LL; Ponikowski P; Samani NJ; van Veldhuisen DJ; Zwinderman AH; Rossignol P; Zannad F; Voors AA; van der Meer P
    Eur J Heart Fail; 2018 May; 20(5):923-930. PubMed ID: 29327797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between renin-angiotensin system inhibitor use and mortality/morbidity in elderly patients with heart failure with reduced ejection fraction: a prospective propensity score-matched cohort study.
    Savarese G; Dahlström U; Vasko P; Pitt B; Lund LH
    Eur Heart J; 2018 Dec; 39(48):4257-4265. PubMed ID: 30351407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renin-angiotensin system inhibitors for patients with mild or moderate chronic kidney disease and heart failure with mildly reduced or preserved ejection fraction.
    Takeuchi S; Kohno T; Goda A; Shiraishi Y; Kitamura M; Nagatomo Y; Takei M; Nomoto M; Soejima K; Kohsaka S; Yoshikawa T;
    Int J Cardiol; 2024 Aug; 409():132190. PubMed ID: 38761975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial.
    Anand IS; Rector TS; Cleland JG; Kuskowski M; McKelvie RS; Persson H; McMurray JJ; Zile MR; Komajda M; Massie BM; Carson PE
    Circ Heart Fail; 2011 Sep; 4(5):569-77. PubMed ID: 21715583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unravelling the interplay between hyperkalaemia, renin-angiotensin-aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC-HFA-EORP Heart Failure Long-Term Registry.
    Rossignol P; Lainscak M; Crespo-Leiro MG; Laroche C; Piepoli MF; Filippatos G; Rosano GMC; Savarese G; Anker SD; Seferovic PM; Ruschitzka F; Coats AJS; Mebazaa A; McDonagh T; Sahuquillo A; Penco M; Maggioni AP; Lund LH;
    Eur J Heart Fail; 2020 Aug; 22(8):1378-1389. PubMed ID: 32243669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes in patients with heart failure with preserved ejection fraction.
    Poppe KK; Doughty RN
    Heart Fail Clin; 2014 Jul; 10(3):503-10. PubMed ID: 24975912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.